Argos Therapeutics Inc (ARGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH133893D
- Pages: 56
- October 2018
- Total Views:1160
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to activate the immune response. Argos is headquartered in Durham, North Carolina, the US.
Argos Therapeutics Inc (ARGS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Argos Therapeutics Raises USD 16 Million In Venture Financing 16
Argos Therapeutics Raises USD 25 Million In Series D Financing 17
Partnerships 19
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Licensing Agreements 21
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Equity Offering 27
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Debt Offering 42
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc-Key Competitors 43
Argos Therapeutics Inc-Key Employees 44
Argos Therapeutics Inc-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 46
Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 49
Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 51
Corporate Communications 53
Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 53
Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54
Other Significant Developments 55
Nov 28, 2017: Argos Provides Financial Update 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List Of Figure
List of Figures
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Argos Therapeutics Raises USD 16 Million In Venture Financing 16
Argos Therapeutics Raises USD 25 Million In Series D Financing 17
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc, Key Competitors 43
Argos Therapeutics Inc, Key Employees 44
Argos Therapeutics Inc, Subsidiaries 45
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Argos Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to activate the immune response. Argos is headquartered in Durham, North Carolina, the US.
Argos Therapeutics Inc (ARGS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Argos Therapeutics Raises USD 16 Million In Venture Financing 16
Argos Therapeutics Raises USD 25 Million In Series D Financing 17
Partnerships 19
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Licensing Agreements 21
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Equity Offering 27
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Debt Offering 42
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc-Key Competitors 43
Argos Therapeutics Inc-Key Employees 44
Argos Therapeutics Inc-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 46
Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 49
Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 51
Corporate Communications 53
Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 53
Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54
Other Significant Developments 55
Nov 28, 2017: Argos Provides Financial Update 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List Of Figure
List of Figures
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Argos Therapeutics Raises USD 16 Million In Venture Financing 16
Argos Therapeutics Raises USD 25 Million In Series D Financing 17
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc, Key Competitors 43
Argos Therapeutics Inc, Key Employees 44
Argos Therapeutics Inc, Subsidiaries 45
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Argos Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020